Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2

Abstract Background The ongoing COVID-19 pandemic has resulted in 185 million recorded cases and over 4 million deaths worldwide. Several COVID-19 vaccines have been approved for emergency use in humans and are being used in many countries. However, all the approved vaccines are administered by intr...

Descripció completa

Dades bibliogràfiques

Autors principals:	Huibi Cao, Juntao Mai, Zhichang Zhou, Zhijie Li, Rongqi Duan, Jacqueline Watt, Ziyan Chen, Ranmal Avinash Bandara, Ming Li, Sang Kyun Ahn, Betty Poon, Natasha Christie-Holmes, Scott D. Gray-Owen, Arinjay Banerjee, Karen Mossman, Rob Kozak, Samira Mubareka, James M. Rini, Jim Hu, Jun Liu
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2021-12-01
Col·lecció:	Cell & Bioscience
Matèries:	COVID-19 HD-Ad Nasal delivery SARS-CoV2 Vaccine
Accés en línia:	https://doi.org/10.1186/s13578-021-00723-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!